9.14
Precedente Chiudi:
$9.13
Aprire:
$9.19
Volume 24 ore:
42,313
Relative Volume:
0.18
Capitalizzazione di mercato:
$432.88M
Reddito:
$62.02M
Utile/perdita netta:
$-45.65M
Rapporto P/E:
-9.9348
EPS:
-0.92
Flusso di cassa netto:
$-9.60M
1 W Prestazione:
+6.37%
1M Prestazione:
-2.24%
6M Prestazione:
+4.32%
1 anno Prestazione:
-2.96%
Theravance Biopharma Inc Stock (TBPH) Company Profile
Nome
Theravance Biopharma Inc
Settore
Industria
Telefono
650-808-6000
Indirizzo
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Confronta TBPH con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
TBPH
Theravance Biopharma Inc
|
9.145 | 432.88M | 62.02M | -45.65M | -9.60M | -0.92 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
490.08 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
577.44 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
599.32 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.66 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
249.34 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-08-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
2024-04-12 | Iniziato | BTIG Research | Buy |
2024-01-08 | Downgrade | Evercore ISI | Outperform → In-line |
2022-05-23 | Iniziato | SVB Leerink | Outperform |
2021-11-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
2021-09-15 | Downgrade | JP Morgan | Overweight → Underweight |
2021-08-25 | Downgrade | Morgan Stanley | Overweight → Underweight |
2021-08-24 | Downgrade | Cowen | Outperform → Market Perform |
2020-10-14 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2020-07-07 | Iniziato | JP Morgan | Overweight |
2020-06-15 | Iniziato | Morgan Stanley | Equal-Weight |
2020-05-13 | Iniziato | Cowen | Outperform |
2020-01-08 | Reiterato | H.C. Wainwright | Buy |
2019-11-06 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
2019-10-29 | Iniziato | H.C. Wainwright | Buy |
2018-03-29 | Ripresa | Piper Jaffray | Overweight |
2017-08-17 | Iniziato | Evercore ISI | Outperform |
2017-06-16 | Iniziato | Cantor Fitzgerald | Overweight |
2017-05-11 | Reiterato | Needham | Buy |
2016-12-21 | Iniziato | Needham | Buy |
2016-11-03 | Iniziato | Piper Jaffray | Overweight |
2016-10-12 | Downgrade | Robert W. Baird | Neutral → Underperform |
2016-08-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
2016-06-20 | Iniziato | Guggenheim | Buy |
2016-06-20 | Reiterato | Leerink Partners | Outperform |
2016-05-12 | Iniziato | Leerink Partners | Outperform |
2016-05-05 | Downgrade | BofA/Merrill | Buy → Neutral |
2015-02-03 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
Mostra tutto
Theravance Biopharma Inc Borsa (TBPH) Ultime notizie
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by Alliancebernstein L.P. - Defense World
(TBPH) Trading Signals - news.stocktradersdaily.com
Vanguard Group Inc. Lowers Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma, Inc. (NASDAQ:TBPH) Position Trimmed by Corebridge Financial Inc. - Defense World
Wellington Management Group LLP Raises Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
KLP Kapitalforvaltning AS Acquires New Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
American Century Companies Inc. Acquires 8,289 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma at Jones Conference: Strategic Growth and Future Prospects - Investing.com Canada
Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting - PR Newswire
Teacher Retirement System of Texas Takes $103,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance biopharma SVP Rhonda Farnum sells $36,000 in shares - MSN
Theravance Biopharma to Participate in an Upcoming Investor Conference - Longview News-Journal
Exclusive Access: Theravance Biopharma Leadership Reveals Strategy at Jones Healthcare Conference - Stock Titan
Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report? - Yahoo Finance
Charles Schwab Investment Management Inc. Has $2.77 Million Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology - PR Newswire
Bank of New York Mellon Corp Sells 5,282 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $13.75 Consensus Price Target from Brokerages - Defense World
Q1 EPS Forecast for Theravance Biopharma Reduced by Analyst - Defense World
(TBPH) Investment Analysis - news.stocktradersdaily.com
Theravance Biopharma (NASDAQ:TBPH) Stock Crosses Above 50-Day Moving Average – What’s Next? - Defense World
Theravance Biopharma: Clinical Progress Is Not Enough To Make It Attractive - Seeking Alpha
Rhumbline Advisers Sells 3,110 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma Inc to Host Earnings Call - ACCESS Newswire
Theravance Biopharma, Inc. to Host Earnings Call - ACCESS Newswire
Zacks Research Brokers Lower Earnings Estimates for TBPH - Armenian Reporter
What is Zacks Research’s Forecast for TBPH Q1 Earnings? - Defense World
Where are the Opportunities in (TBPH) - news.stocktradersdaily.com
Equities Analysts Issue Forecasts for TBPH FY2028 Earnings - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Share Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - MarketBeat
HC Wainwright Reiterates Buy Rating for Theravance Biopharma (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma Reports Strong Q4 2024 Earnings - TipRanks
Investor Network: Theravance Biopharma Inc to Host Earnings Call - ACCESS Newswire
Research Analysts Issue Forecasts for TBPH FY2024 Earnings - Defense World
Theravance Biopharma (NASDAQ:TBPH) Releases Earnings Results, Misses Estimates By $0.26 EPS - MarketBeat
Theravance's Q4 Loss In Line With Estimates, Sales Beat - Yahoo
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call Transcript - Insider Monkey
FY2024 Earnings Forecast for TBPH Issued By HC Wainwright - MarketBeat
HC Wainwright Reiterates “Buy” Rating for Theravance Biopharma (NASDAQ:TBPH) - Defense World
Theravance Biopharma Inc (TBPH) Q4 2024 Earnings Call Highlights: Record Sales and Strategic ... By GuruFocus - Investing.com Canada
Theravance Biopharma Inc (TBPH) Q4 2024 Earnings Call Highlights: Record Sales and Strategic ... - Yahoo Finance
What is HC Wainwright’s Estimate for TBPH FY2028 Earnings? - Defense World
Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates - MSN
Theravance Biopharma Reports Record 2024 Financial Results - TipRanks
Theravance Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results - PR Newswire
Theravance Biopharma Inc Reports Q4 2024 Earnings: YUPELRI Sales Reach $66.7 Million, TRELEGY Milestone Achieved - GuruFocus
Earnings To Watch: Theravance Biopharma Inc (TBPH) Reports Q4 20 - GuruFocus
Earnings To Watch: Theravance Biopharma Inc (TBPH) Reports Q4 2024 Result - Yahoo Finance
Theravance Biopharma: Strategic Milestones and Revenue Forecasts Justify Buy Rating - TipRanks
Theravance Biopharma Inc Azioni (TBPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):